Smarter oncology second opinion — AI-powered, expert-reviewed, using your existing NGS report.
Read More
CAMBRIDGE, Mass., July 15, 2026: Genomate Health, a precision oncology company developing computational reasoning technology for cancer treatment planning, today announced the launch of a research collaboration with Inflexa, a company specializing in AI-powered multi-omics analysis. The collaboration brings together complementary scientific approaches to better understand biological differences underlying differential drug responses of molecularly defined cohorts.
As part of the collaboration, Genomate Health will use its computational reasoning platform to define biologically meaningful patient and disease cohorts based on molecular context. Inflexa will then apply its multi-omics analytics platform to these cohorts to identify biological patterns that may not be apparent from genomic data alone.
"Some of the most important scientific discoveries begin with observations that challenge existing biological assumptions," said Dr. Istvan Petak, Founder and Chief Scientific Officer of Genomate Health. "Our computational reasoning model identifies therapeutic opportunities by analyzing the complete molecular context of each tumor. By combining this approach with Inflexa's multi-omics analytics, we hope to better understand why certain tumors behave differently than expected and uncover biological signals that may ultimately improve precision oncology."
The collaboration reflects a shared commitment to advancing precision medicine through complementary computational approaches. Genomate's platform integrates genomic alterations and their biological interactions to prioritize therapies, while Inflexa's technology analyzes multiple layers of omics data to discover novel biomarkers and biological pathways.
"A tumor's genome tells you what it is capable of, not always what it is doing," said Radu Tanasa, Co-founder and CEO of Inflexa. "The cases worth understanding are usually the ones that don't respond the way their molecular profile suggests, and the reason tends to sit in the other omics layers. We're pairing Genomate's molecular reasoning with multi-omics analysis, cross-checked across independent methods, to surface those signals and see which ones actually hold up as biomarkers."
If successful, the collaboration could provide a framework for future research into exceptional responders, resistance mechanisms, and biomarker discovery across additional targeted therapies.
About Genomate Health
Genomate Health is a precision medicine company developing a novel computational infrastructure for precision oncology, grounded in over 20 years of molecular oncology research. Its technology, Genomate®, has been validated in multiple studies, with tumor response and clinical outcome data published in major peer-reviewed journals and forums, including Nature NPJ Precision Oncology, ASCO, AACR, and ESMO. Genomate Health is certified to ISO 13485 and ISO 27001 standards, is a founding member of CancerX, and a Mayo Clinic Platform_Accelerate graduate. Genomate has been awarded by the ASCO Breakthrough Innovations in Oncology Conference and has won the prestigious Future Unicorn Award of DIGITALEUROPE.
Learn more at www.genomate.health.
About Inflexa
Inflexa develops multi-omics analysis technology for computational biology, used in research from preclinical studies through translational science. Its analysis engine plans and runs multi-step analyses across transcriptomic, proteomic, and other omics layers, and reports the findings that hold up across independent methods rather than a single pipeline. Every result carries a provenance record of its methods, parameters, and source data, aligned with the W3C PROV standard and cryptographically signed. Inflexa's technology supports biomarker discovery, mechanism-of-action analysis, responder stratification, and target validation across precision medicine.
Learn more at www.inflexa.ai.
Media contact
Alina Luchian
alina.luchian(@)genomate.health
.avif)
